Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
Prognostic value of neurofilament light chain protein and glial fibrillary acidic protein in multiple sclerosis subtypes and disease activity patterns: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Cheng, Jiang Chenxi, Wang Yiren, Hu Yiheng, Li Yunfei, Zhou Ping, Wang Youhua
Аннотация
BACKGROUND: Neurofilament light chain protein and glial fibrillary acidic protein have been proposed as potential blood biomarkers for multiple sclerosis. However, their diagnostic and prognostic values across different subtypes and disease activity patterns remain unclear.
METHODS: We systematically searched major databases (inception to February 13, 2025). A total of thirteen studies including 4,016 individuals were incorporated. A random-effects meta-analysis methodology was applied to assess the forecasting capabilities of NfL and GFAP concerning multiple sclerosis relapses and the advancement of disability. Subgroup examinations were executed according to disease classifications and the observed activity levels.
RESULTS: Treated as a continuous measure, NfL exhibited a 4% increase in risk for adverse events with each individual unit escalation (RR = 1.04, 95% CI: 1.01-1.06, P < 0.001). Subgroup analyses revealed that predictive power was stronger in RRMS compared with mixed type (RR = 3.82 vs. 1.03, P < 0.01), and was statistically significant for neurodegenerative progression (EDSS worsening without inflammation) (RR = 1.03, P < 0.05). Using a threshold, NfL levels above the cutoff increased risk 2.61-fold (RR = 2.61, 95% CI: 1.74-3.92). GFAP showed no significant overall prognostic value (RR = 1.01, P = 0.18), with no subgroup differences.
CONCLUSION: NfL is a sensitive biomarker for RRMS and neurodegenerative progression, with its value dependent on subtype and activity pattern. No evidence supports GFAP as an independent prognostic marker. Precise MS subtyping is crucial for clinical biomarker application.
METHODS: We systematically searched major databases (inception to February 13, 2025). A total of thirteen studies including 4,016 individuals were incorporated. A random-effects meta-analysis methodology was applied to assess the forecasting capabilities of NfL and GFAP concerning multiple sclerosis relapses and the advancement of disability. Subgroup examinations were executed according to disease classifications and the observed activity levels.
RESULTS: Treated as a continuous measure, NfL exhibited a 4% increase in risk for adverse events with each individual unit escalation (RR = 1.04, 95% CI: 1.01-1.06, P < 0.001). Subgroup analyses revealed that predictive power was stronger in RRMS compared with mixed type (RR = 3.82 vs. 1.03, P < 0.01), and was statistically significant for neurodegenerative progression (EDSS worsening without inflammation) (RR = 1.03, P < 0.05). Using a threshold, NfL levels above the cutoff increased risk 2.61-fold (RR = 2.61, 95% CI: 1.74-3.92). GFAP showed no significant overall prognostic value (RR = 1.01, P = 0.18), with no subgroup differences.
CONCLUSION: NfL is a sensitive biomarker for RRMS and neurodegenerative progression, with its value dependent on subtype and activity pattern. No evidence supports GFAP as an independent prognostic marker. Precise MS subtyping is crucial for clinical biomarker application.